Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Inflammatory cytokines TNF-α and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators
Tayyab Rehman, … , Pradeep K. Singh, Michael J. Welsh
Tayyab Rehman, … , Pradeep K. Singh, Michael J. Welsh
Published June 24, 2021
Citation Information: J Clin Invest. 2021;131(16):e150398. https://doi.org/10.1172/JCI150398.
View: Text | PDF
Research Article Pulmonology Article has an altmetric score of 5

Inflammatory cytokines TNF-α and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators

  • Text
  • PDF
Abstract

Without cystic fibrosis transmembrane conductance regulator–mediated (CFTR-mediated) HCO3– secretion, airway epithelia of newborns with cystic fibrosis (CF) produce an abnormally acidic airway surface liquid (ASL), and the decreased pH impairs respiratory host defenses. However, within a few months of birth, ASL pH increases to match that in non-CF airways. Although the physiological basis for the increase is unknown, this time course matches the development of inflammation in CF airways. To learn whether inflammation alters CF ASL pH, we treated CF epithelia with TNF-α and IL-17 (TNF-α+IL-17), 2 inflammatory cytokines that are elevated in CF airways. TNF-α+IL-17 markedly increased ASL pH by upregulating pendrin, an apical Cl–/HCO3– exchanger. Moreover, when CF epithelia were exposed to TNF-α+IL-17, clinically approved CFTR modulators further alkalinized ASL pH. As predicted by these results, in vivo data revealed a positive correlation between airway inflammation and CFTR modulator–induced improvement in lung function. These findings suggest that inflammation is a key regulator of HCO3– secretion in CF airways. Thus, they explain earlier observations that ASL pH increases after birth and indicate that, for similar levels of inflammation, the pH of CF ASL is abnormally acidic. These results also suggest that a non-cell-autonomous mechanism, airway inflammation, is an important determinant of the response to CFTR modulators.

Authors

Tayyab Rehman, Philip H. Karp, Ping Tan, Brian J. Goodell, Alejandro A. Pezzulo, Andrew L. Thurman, Ian M. Thornell, Samantha L. Durfey, Michael E. Duffey, David A. Stoltz, Edward F. McKone, Pradeep K. Singh, Michael J. Welsh

×

Total citations by year

Year: 2025 2024 2023 2022 2021 Total
Citations: 1 14 5 9 2 31
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (31)

Title and authors Publication Year
Deleterious effect of P. aeruginosa on F508del-CFTR rescued by Elezacaftor/Tezacaftor/Ivacaftor is clinical strain dependent in patient-derived nasal cells: first step toward personalized medicine.
Caterina Allegretta, Enza Montemitro, Maria Noemi Sgobba, Valeria Capurro, Emanuela Pesce, Fabiana Ciciriello, Gianfranco La Bella, Martina Rossito, Vanessa Tuccio, Fabio Arena, Tarini Gunawardena, Lorenzo Guerra, Nicoletta Pedemonte, Claudia Piccoli, Onofrio Laselva
ERJ open research 2025
Cystic fibrosis airway inflammation enables elexacaftor/tezacaftor/ivacaftor-mediated rescue of N1303K CFTR mutation
Gentzsch M, Baker B, Cholon DM, Kam CW, McKinzie CJ, Despotes KA, Boyles SE, Quinney NL, Esther CR Jr, Ribeiro CM
ERJ Open Research 2024
Multiple Regulatory Signals and Components in the Modulation of Bicarbonate Transporters.
Kim HJ, Hong JH
Pharmaceutics 2024
Representation and quantification of module activity from omics data with rROMA.
Najm M, Cornet M, Albergante L, Zinovyev A, Sermet-Gaudelus I, Stoven V, Calzone L, Martignetti L
npj Systems Biology and Applications 2024
TWO RARE VARIANTS THAT AFFECT THE SAME AMINO ACID IN CFTR HAVE DISTINCT RESPONSES TO IVACAFTOR
Li H, Rodrat M, Al-Salmani MK, Veselu DF, Han ST, Raraigh KS, Cutting GR, Sheppard DN
The Journal of Physiology 2024
Epithelial responses to CFTR modulators are improved by inflammatory cytokines and impaired by anti-inflammatory drugs
Tayyab Rehman, Alejandro Pezzulo, Andrew Thurman, Rachel Zemans, Michael Welsh
JCI Insight 2024
Editorial: Advancing therapeutic strategies: exploring ABC transporters and chemicals affecting their expression and function for disease treatment
Veit G, Matsuo M, Okiyoneda T
Frontiers in pharmacology 2024
Dynamic measurement of airway surface liquid volume with an ex vivo trachea-chip
Scott M, Lei L, Bierstedt KC, McCray PB Jr, Xie Y
Lab on a Chip 2024
Comparison of a novel potentiator of CFTR channel activity to ivacaftor in ameliorating mucostasis caused by cigarette smoke in primary human bronchial airway epithelial cells
Tanjala AC, Jiang JX, Eckford PD, Ramjeesingh M, Li C, Huan LJ, Langeveld G, Townsend C, Paone DV, Busch-Petersen J, Pekhletski R, Tang L, Raju V, Rowe SM, Bear CE
Respiratory Research 2024
Disease-specific transcriptional programs govern airway goblet cell metaplasia
Li K, Song Z, Yue Q, Wang Q, Li Y, Zhu Y, Chen H
Heliyon 2024
Cystic fibrosis.
Mall MA, Burgel PR, Castellani C, Davies JC, Salathe M, Taylor-Cousar JL
Nature Reviews Disease Primers 2024
Predictors of Sinonasal Improvement After Highly Effective Modulator Therapy in Adults with Cystic Fibrosis.
Beswick DM, Liu CM, Overdevest JB, Zemke A, Khatiwada A, Gudis DA, Miller JE, Kimple A, Tervo JP, DiMango E, Goralski JL, Keating C, Senior B, Stapleton AL, Eshaghian PH, Mace JC, Markarian K, Alt JA, Bodner TE, Chowdhury NI, Getz AE, Hwang PH, Khanwalker A, Lee JT, Li DA, Norris M, Nayak JV, Owens C, Patel ZM, Poch K, Schlosser RJ, Smith KA, Smith TL, Soler ZM, Suh JD, Turner GA, Wang MB, Saavedra MT, Taylor Cousar JL
The Laryngoscope 2024
Allergic Bronchopulmonary Aspergillosis (ABPA) in the Era of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
Chatterjee P, Moss CT, Omar S, Dhillon E, Hernandez Borges CD, Tang AC, Stevens DA, Hsu JL
Journal of Fungi 2024
From CFTR to a CF signalling network: a systems biology approach to study Cystic Fibrosis
Najm M, Martignetti L, Cornet M, Kelly-Aubert M, Sermet I, Calzone L, Stoven V
BMC Genomics 2024
Impact of Gene Modifiers on Cystic Fibrosis Phenotypic Profiles: A Systematic Review
Ward A, Mauleon R, Ooi CY, Rosic N
Human Mutation 2024
Revisiting Host-Pathogen Interactions in Cystic Fibrosis Lungs in the Era of CFTR Modulators
Ribeiro CM, Higgs MG, Muhlebach MS, Wolfgang MC, Borgatti M, Lampronti I, Cabrini G
International journal of molecular sciences 2023
Inflammation as a Regulator of the Airway Surface Liquid pH in Cystic Fibrosis
Rehman T, Welsh MJ
Cells 2023
Lung Inflammatory Genes in Cystic Fibrosis and Their Relevance to Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapies
Carbone A, Vitullo P, Di Gioia S, Conese M
Genes & development 2023
Pathogenicity and virulence of Aspergillus fumigatus
Earle K, Valero C, Conn DP, Vere G, Cook PC, Bromley MJ, Bowyer P, Gago S
Virulence 2023
Putting bicarbonate on the spot: pharmacological insights for CFTR correction in the airway epithelium
Zajac M, Lepissier A, Dréano E, Chevalier B, Hatton A, Kelly-Aubert M, Guidone D, Planelles G, Edelman A, Girodon E, Hinzpeter A, Crambert G, Pranke I, Galietta LJ, Sermet-Gaudelus I
Frontiers in pharmacology 2023
Losartan ameliorates TGF-β1-induced CFTR dysfunction and improves correction by cystic fibrosis modulator therapies
Michael D. Kim, Charles Bengtson, Makoto Yoshida, Asef J. Niloy, John Dennis, Nathalie Baumlin, Matthias Salathe
Journal of Clinical Investigation 2022
Ivacaftor Alters Macrophage and Lymphocyte Infiltration in the Lungs Following Lipopolysaccharide Exposure
Harwood KH, McQuade RM, Jarnicki A, Schneider-Futschik EK
2022
IL-17 Cytokines and Chronic Lung Diseases
Ritzmann F, Lunding LP, Bals R, Wegmann M, Beisswenger C
Cells 2022
The surface of airway epithelia exposed to IL-17/TNF-α switches between a hyperviscous and a fluid state under beta-adrenergic control
Daniela Guidone, Martina Buccirossi, Paolo Scudieri, Michele Genovese, Sergio Sarnataro, Rossella Cegli, Federico Cresta, Vito Terlizzi, Gabrielle Planelles, Gilles Crambert, Isabelle Sermet, Luis Galietta
JCI Insight 2022
The CFTR Amplifier Nesolicaftor Rescues TGF-β1 Inhibition of Modulator-Corrected F508del CFTR Function
Bengtson C, Silswal N, Baumlin N, Yoshida M, Dennis J, Yerrathota S, Kim M, Salathe M
International journal of molecular sciences 2022
WNK Inhibition Increases Surface Liquid pH and Host Defense in Cystic Fibrosis Airway Epithelia.
Rehman T, Karp PH, Thurman AL, Mather SE, Jain A, Cooney AL, Sinn PL, Pezzulo AA, Duffey ME, Welsh MJ
American journal of respiratory cell and molecular biology 2022
A Nod and a WNK (Kinase): Understanding Airway Surface Liquid pH.
Cook DP, Peebles RS Jr
American journal of respiratory cell and molecular biology 2022
Impact of CFTR Modulators on the Impaired Function of Phagocytes in Cystic Fibrosis Lung Disease.
Meoli A, Eickmeier O, Pisi G, Fainardi V, Zielen S, Esposito S
International journal of molecular sciences 2022
The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation
Caverly LJ, Riquelme SA, Hisert KB
Clinics in Chest Medicine 2022
Bicarbonate Transport in Cystic Fibrosis and Pancreatitis
D Angyal, M Bijvelds, M Bruno, M Peppelenbosch, H de Jonge
Cells 2021
Impact of Airway Inflammation on the Efficacy of CFTR Modulators
CM Ribeiro, M Gentzsch
Cells 2021

← Previous 1 2 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 7 X users
On 1 Facebook pages
47 readers on Mendeley
See more details